<DOC>
	<DOC>NCT02565758</DOC>
	<brief_summary>This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with advanced solid tumors.</brief_summary>
	<brief_title>ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1. Participants with advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. 3. Participants must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens: Participants with nonevaluable or nonmeasurable cancer are eligible if they have a confirmed increase in tumor antigens &gt;=2 x upper limit of normal (ULN). 4. All participants must consent to provide archived diagnostic formalinfixed paraffin embedded (FFPE) tumor tissue, if available. 5. Participant has adequate bone marrow, renal, hepatic and cardiac function. 6. Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment. 1. Participant has received anticancer therapy or any investigational therapy within a period of 21 days prior to the first dose of ABBV085. 2. Uncontrolled metastases to the central nervous system (CNS). Participants with brain metastases are eligible provided they have shown clinical and radiographic stable disease for at least 4 weeks after definitive therapy and have not used steroids for at least 4 weeks prior to first dose of ABBV085. 3. Unresolved adverse events &gt;= Grade 2 from prior anticancer therapy, except for alopecia. 4. Participant has ongoing hemolysis. 5. Major surgery within &lt;=28 days prior to the first dose of ABBV085. 6. Clinically significant uncontrolled condition(s). 7. Participant has history of major immunologic reaction to any auristatinbased and /or Immunoglobulin G (IgG) containing agent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoplasm</keyword>
</DOC>